Asia Pacific offers significant opportunities for clinical development, with diverse patient populations, established research infrastructure and access to experienced investigators across a broad range of therapeutic areas.
However, successful clinical trial delivery across the region requires more than geographic coverage. Each market presents different regulatory requirements, ethics approval processes, healthcare systems and site-level considerations.
Southern Star Research brings together regional clinical operations experience, local market knowledge and coordinated project oversight to support sponsors throughout the clinical trial lifecycle.
Southern Star Research supports clinical trials across established and emerging research markets throughout the Asia Pacific region.
As our headquarters and a key clinical research market, Australia provides access to experienced investigators, established early-phase facilities and a regulatory environment well suited to early clinical development.
Our Australian teams support Phase I–III clinical trials, including first-in-human studies, complex clinical programs and multi-site studies across a range of therapeutic areas.
Singapore is an important centre for clinical research and regional coordination in Southeast Asia, with established research institutions, experienced investigators and advanced healthcare infrastructure.
Our presence in Singapore strengthens regional coordination and supports sponsors conducting clinical trials across Southeast Asian markets.
India offers access to large and diverse patient populations, experienced clinical research sites and significant opportunities for multi-centre clinical trials.
Our presence in Mumbai supports regional clinical operations and coordination for sponsors evaluating India as part of their clinical development strategy.
Beyond our physical offices, Southern Star Research has operational capabilities and regional networks extending across:
Our regional approach allows sponsors to assess individual countries or develop multi-country clinical trial strategies based on therapeutic requirements, patient populations, regulatory pathways and study objectives.
Access to suitable clinical trial sites and experienced investigators is fundamental to successful study delivery, particularly when conducting research across multiple APAC countries.
Southern Star Research works with clinical research sites, investigators, specialist service providers and regional partners to support efficient study planning and execution.
Our approach to site selection combines local market knowledge with study-specific feasibility assessments.
We work to identify sites with the appropriate therapeutic expertise, patient populations, research infrastructure and operational capacity to support each protocol.
By engaging with investigators and sites early in the planning process, we help sponsors assess recruitment potential, identify operational challenges and develop realistic study timelines.
Multi-country clinical trials frequently require coordination across central and local laboratories, imaging providers, investigational product logistics, clinical technology providers and other specialist services.
We work with regional and local vendors to support study requirements, maintaining oversight of quality, timelines and operational responsibilities.
Our regional capabilities allow us to combine local execution with consistent clinical trial management and quality oversight.
This approach supports communication between sponsors, sites, vendors and project teams while accounting for country-specific regulatory and operational requirements.
Australia is an established destination for early-phase clinical trials, offering experienced Phase I units, a supportive regulatory framework and potential financial advantages for eligible research and development activities.
Southern Star Research supports sponsors navigating early clinical development, from feasibility and protocol planning through to study start-up, recruitment and clinical trial delivery.
As clinical programs progress into later phases, sponsors often require access to larger and more diverse patient populations across multiple countries.
Expanding clinical trials across Asia Pacific can provide additional recruitment opportunities and access to specialist research centres. However, it also introduces greater operational complexity.
Southern Star Research supports the planning and execution of multi-country Phase II and III clinical trials through coordinated project management, regional clinical expertise and consistent quality oversight.
Our approach focuses on maintaining protocol consistency, managing country-specific requirements and supporting reliable data collection across participating sites.
Access to clinical research capabilities across key Asia Pacific markets, supported by local knowledge of regulatory requirements, healthcare systems and clinical research practices.
Experienced clinical development and operational professionals who work closely with sponsors, providing responsive communication and accountability throughout the clinical trial lifecycle.
Relationships with investigators, clinical research sites and specialist service providers to support feasibility, site selection and clinical trial delivery.
Full-service CRO capabilities spanning clinical strategy, regulatory support, clinical operations, biometrics, data management and medical writing.
A coordinated approach to clinical trial management, supported by established quality systems and standard operating procedures across par
A coordinated approach to clinical trial management, supported by established quality systems and standard operating procedures across participating countries.
icipating countries.
Whether you are planning an early-phase clinical trial in Australia, evaluating new patient populations in Asia or preparing for a multi-country Phase II or III study, Southern Star Research can help you assess the opportunities across the region.
Connect with our team to discuss your clinical development program, regional feasibility and clinical trial requirements.